{"generic":"Dasabuvir","drugs":["Dasabuvir"],"mono":{"0":{"id":"jym2s0","title":"Generic Names","mono":"Dasabuvir"},"1":{"id":"jym2s1","title":"Dosing and Indications","sub":[{"id":"jym2s1b4","title":"Adult Dosing","mono":"<ul><li>Dasabuvir has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU).<\/li><li>Efficacy and safety not established in patients with hepatitis C and hepatitis B coinfection.<\/li><li><b>Hepatitis C, chronic, Genotype 1a or 1b - HIV infection:<\/b> HCV genotype 1a without cirrhosis: 250 mg orally twice daily in the morning and evening with food in combination with ombitasvir\/paritaprevir\/ritonavir plus ribavirin (and HIV antiviral agents); continue HCV treatment for 12 weeks<\/li><li><b>Hepatitis C, chronic, Genotype 1a or 1b - HIV infection:<\/b> HCV genotype 1a with compensated cirrhosis: 250 mg orally twice daily in the morning and evening with food in combination with ombitasvir\/paritaprevir\/ritonavir plus ribavirin (and HIV antiviral agents); continue HCV treatment for 24 weeks<\/li><li><b>Hepatitis C, chronic, Genotype 1a or 1b - HIV infection:<\/b> HCV genotype 1b without cirrhosis: 250 mg orally twice daily in the morning and evening with food in combination with ombitasvir\/paritaprevir\/ritonavir (and HIV antiviral agents); continue HCV treatment for 12 weeks<\/li><li><b>Hepatitis C, chronic, Genotype 1a or 1b - HIV infection:<\/b> HCV genotype 1b with compensated cirrhosis: 250 mg orally twice daily in the morning and evening with food in combination with ombitasvir\/paritaprevir\/ritonavir plus ribavirin (and HIV antiviral agents); continue HCV treatment for 12 weeks<\/li><li><b>Hepatitis C, chronic, Genotype 1a or 1b - HIV infection:<\/b> Missed dose: If dose cannot be taken within 6 hours, skip that dose and take the next dose at the usual time<\/li><li><b>Hepatitis C, chronic, Genotype 1a or 1b - Transplantation of liver:<\/b> 250 mg ORALLY twice daily in the morning and evening with food in combination with ombitasvir\/paritaprevir\/ritonavir plus ribavirin; consider lower ribavirin dose at initiation (ribavirin study dose, 600 to 800 mg\/day); continue treatment for 24 weeks<\/li><li><b>Hepatitis C, chronic, Genotype 1a or 1b - Transplantation of liver:<\/b> Missed dose: If dose cannot be taken within 6 hours, skip that dose and take the next dose at the usual time<\/li><li><b>Hepatitis C, chronic, Genotype 1a with compensated cirrhosis:<\/b> 250 mg ORALLY twice daily in the morning and evening with food in combination with ombitasvir\/paritaprevir\/ritonavir plus ribavirin; continue treatment for 24 weeks<\/li><li><b>Hepatitis C, chronic, Genotype 1a with compensated cirrhosis:<\/b> Missed dose: If dose cannot be taken within 6 hours, skip that dose and take the next dose at the usual time<\/li><li><b>Hepatitis C, chronic, Genotype 1a without cirrhosis:<\/b> 250 mg ORALLY twice daily in the morning and evening with food in combination with ombitasvir\/paritaprevir\/ritonavir plus ribavirin; continue treatment for 12 weeks<\/li><li><b>Hepatitis C, chronic, Genotype 1a without cirrhosis:<\/b> Missed dose: If dose cannot be taken within 6 hours, skip that dose and take the next dose at the usual time<\/li><li><b>Hepatitis C, chronic, Genotype 1b with compensated cirrhosis:<\/b> 250 mg ORALLY twice daily in the morning and evening with food in combination with ombitasvir\/paritaprevir\/ritonavir plus ribavirin; continue treatment for 12 weeks<\/li><li><b>Hepatitis C, chronic, Genotype 1b with compensated cirrhosis:<\/b> Missed dose: If dose cannot be taken within 6 hours, skip that dose and take the next dose at the usual time<\/li><li><b>Hepatitis C, chronic, Genotype 1b without cirrhosis:<\/b> 250 mg ORALLY twice daily in the morning and evening with food in combination with ombitasvir\/paritaprevir\/ritonavir; continue treatment for 12 weeks<\/li><li><b>Hepatitis C, chronic, Genotype 1b without cirrhosis:<\/b> Missed dose: If dose cannot be taken within 6 hours, skip that dose and take the next dose at the usual time<\/li><\/ul>"},{"id":"jym2s1b5","title":"Pediatric Dosing","mono":"Efficacy and safety not established in patients younger than 18 years."},{"id":"jym2s1b6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment:<\/b> No dosage adjustment required<\/li><li><b>Hepatic impairment, mild (Child-Pugh class A):<\/b> No dosage adjustment required<\/li><li><b>Hepatic impairment, moderate (Child-Pugh class B):<\/b> No dosage adjustment expected based on pharmacokinetic studies; efficacy and safety not established<\/li><li><b>Hepatic impairment, severe (Child-Pugh class C):<\/b> Do not use<\/li><li><b>Elderly:<\/b> No dosage adjustment required<\/li><\/ul>"},{"id":"jym2s1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><ul><li>Hepatitis C, chronic, Genotype 1a or 1b - HIV infection<\/li><li>Hepatitis C, chronic, Genotype 1a or 1b - Transplantation of liver<\/li><li>Hepatitis C, chronic, Genotype 1a with compensated cirrhosis<\/li><li>Hepatitis C, chronic, Genotype 1a without cirrhosis<\/li><li>Hepatitis C, chronic, Genotype 1b with compensated cirrhosis<\/li><li>Hepatitis C, chronic, Genotype 1b without cirrhosis<\/li><\/ul>"}]},"3":{"id":"jym2s3","title":"Contraindications\/Warnings","sub":[{"id":"jym2s3b9","title":"Contraindications","mono":"<ul><li>Concomitant use of ethinyl estradiol-containing products (ie, oral contraceptives or contraceptive vaginal rings); increased risk of ALT elevations<\/li><li>Concomitant use of strong CYP2C8 inhibitors (ie, gemfibrozil)<\/li><li>Concomitant use of strong or moderate enzyme inducers (ie, carbamazepine, phenytoin, phenobarbital, efavirenz, nevirapine, etravirine, enzalutamide, mitotane, rifampicin, or St. John's wort)<\/li><li>Hypersensitivity to dasabuvir or any excipients of the product<\/li><\/ul>"},{"id":"jym2s3b10","title":"Precautions","mono":"<ul><li>Endocrine and Metabolic:<\/li><li>-- Do not use in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption<\/li><li>Hepatic:<\/li><li>-- Use not recommended in patients with severe hepatic impairment; safety not established in moderate impairment<\/li><li>-- ALT elevations have been reported<\/li><li>Reproductive:<\/li><li>-- Fetal harm may occur if ribavirin is administered to a pregnant woman; effective contraception is required during treatment and for at least 6 months following discontinuation<\/li><li>Other:<\/li><li>-- Use not recommended in coinfected HIV patients without suppressive antiretroviral therapy or in those coinfected with hepatitis B<\/li><li>Concomitant Use:<\/li><li>-- Coadministration with antivirals other than ombitasvir, paritaprevir, ribavirin, and ritonavir is not recommended<\/li><\/ul>"},{"id":"jym2s3b11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"jym2s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jym2s4","title":"Drug Interactions","sub":[{"id":"jym2s4b13","title":"Contraindicated","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Ethinyl Estradiol (theoretical)<\/li><li>Etravirine (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Gemfibrozil (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nevirapine (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><\/ul>"},{"id":"jym2s4b14","title":"Major","mono":"<ul><li>Alprazolam (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amlodipine (theoretical)<\/li><li>Ataluren (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Belinostat (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Buprenorphine (theoretical)<\/li><li>Cabazitaxel (theoretical)<\/li><li>Captopril (theoretical)<\/li><li>Carvedilol (theoretical)<\/li><li>Cladribine (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clofarabine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Conjugated Estrogens (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Dactinomycin (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Daunorubicin (theoretical)<\/li><li>Deferasirox (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Diethylstilbestrol (theoretical)<\/li><li>Diltiazem (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dolutegravir (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Dronabinol (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Eltrombopag (theoretical)<\/li><li>Elvitegravir (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Estradiol (theoretical)<\/li><li>Estrone (theoretical)<\/li><li>Etoposide (theoretical)<\/li><li>Felodipine (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluticasone (theoretical)<\/li><li>Folic Acid (theoretical)<\/li><li>Furosemide (theoretical)<\/li><li>Gefitinib (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Hesperidin (theoretical)<\/li><li>Hydrocortisone (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Irinotecan (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivermectin (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lamivudine (theoretical)<\/li><li>Lansoprazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Levothyroxine (theoretical)<\/li><li>Lidocaine (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Methotrexate (theoretical)<\/li><li>Mexiletine (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitoxantrone (theoretical)<\/li><li>Montelukast (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nitrofurantoin (theoretical)<\/li><li>Novobiocin (theoretical)<\/li><li>Omeprazole (theoretical)<\/li><li>Oxaliplatin (theoretical)<\/li><li>Pantoprazole (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pravastatin (theoretical)<\/li><li>Prazosin (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Quercetin (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Rabeprazole (theoretical)<\/li><li>Raltegravir (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Riluzole (theoretical)<\/li><li>Rosuvastatin (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sulfasalazine (theoretical)<\/li><li>Sumatriptan (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telmisartan (theoretical)<\/li><li>Teniposide (theoretical)<\/li><li>Teriflunomide (theoretical)<\/li><li>Testosterone (theoretical)<\/li><li>Tocophersolan (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Ulipristal (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}]},"5":{"id":"jym2s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Pruritus (1% to 10% or more)<\/li><li><b>Gastrointestinal:<\/b>Nausea (10% or more)<\/li><li><b>Hematologic:<\/b>Anemia (1% to less than 10%)<\/li><li><b>Neurologic:<\/b>Asthenia (10% or more), Insomnia (10% or more)<\/li><li><b>Other:<\/b>Fatigue (10% or more)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Decreased hemoglobin, Grade 3 or 4 (grade 3, 0.1% to 0.8%; grade 4, 0.3%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised, Grade 3 or 4 (0.2% to 1.1%), Increased bilirubin level, Grade 3 or 4 (0.1% to 9.7%)<\/li><\/ul>"},"6":{"id":"jym2s6","title":"Drug Name Info","sub":{"2":{"id":"jym2s6b19","title":"Class","mono":"Antiviral<br\/>"},"3":{"id":"jym2s6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"jym2s7","title":"Mechanism Of Action","mono":"Dasabuvir is an HCV non-nucleoside NS5B palm polymerase inhibitor. Dasabuvir inhibits replication of the HCV viral genome.<br\/>"},"8":{"id":"jym2s8","title":"Pharmacokinetics","sub":[{"id":"jym2s8b23","title":"Absorption","mono":"<ul><li>Tmax, oral: 4 to 5 hours<\/li><li>Effects of food: AUC increased up to 30%<\/li><\/ul>"},{"id":"jym2s8b24","title":"Distribution","mono":"Protein binding, plasma proteins: 99.5% <br\/>"},{"id":"jym2s8b25","title":"Metabolism","mono":"<ul><li>Metabolites, M1: active<\/li><li>Substrate of CYP2C8 and CYP3A<\/li><li>Inhibitor of BCRP and UGT1A1, UGT1A4, UGT1A6, and intestinal UGT2B7<\/li><\/ul>"},{"id":"jym2s8b26","title":"Excretion","mono":"<ul><li>Renal: 2%<\/li><li>Fecal: 94%; unchanged 26.2%; M1 active metabolite, 31.5%<\/li><\/ul>"},{"id":"jym2s8b27","title":"Elimination Half Life","mono":"6 hours <br\/>"}]},"9":{"id":"jym2s9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>Swallow tablets whole; do not chew, break, or dissolve tablets.<\/li><li>Take with food.<\/li><\/ul>"},"10":{"id":"jym2s10","title":"Monitoring","mono":"<ul><li>determine hepatitis C virus genotype prior to initiation of therapy<\/li><li>reduction in HCV-RNA viral load and improvement in signs\/symptoms of chronic hepatitis C genotype 1 infection may indicate efficacy<\/li><\/ul>"},"13":{"id":"jym2s13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to report symptoms of liver disease.<\/li><li>Encourage patient to avoid activities requiring mental alertness or coordination until drug effects are realized due to potential for fatigue.<\/li><li>Side effects may include anemia, insomnia, nausea, pruritus, or asthenia.<\/li><li>Encourage patient to take drug with food.<\/li><li>Tell patient to take a missed dose as soon as possible, but if next dose is in less than 6 hours, skip the missed dose.<\/li><\/ul>"}}}